5 articles with ORYX
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants.
Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA
ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno-Oncology Drugs
ORYX Enrolls First Patients In A Dose-Escalating Phase I/IIa Pilot Study With Oncolytic Virus Parvoryx To Treat Metastatic Pancreatic Cancer